Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.
Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC. Price TJ, et al. Among authors: weickhardt a. J Clin Oncol. 2011 Jul 1;29(19):2675-82. doi: 10.1200/JCO.2010.34.5520. Epub 2011 Jun 6. J Clin Oncol. 2011. PMID: 21646616 Clinical Trial.
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC. Weickhardt AJ, et al. J Clin Oncol. 2012 May 1;30(13):1505-12. doi: 10.1200/JCO.2011.38.6599. Epub 2012 Mar 12. J Clin Oncol. 2012. PMID: 22412142 Clinical Trial.
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann KP, Simes J, Weickhardt A, Wrin JW, Wilson K, Gebski V, Van Hazel G, Robinson B, Cunningham D, Tebbutt NC. Price TJ, et al. Among authors: weickhardt a. Br J Cancer. 2015 Mar 17;112(6):963-70. doi: 10.1038/bjc.2015.37. Br J Cancer. 2015. PMID: 25742472 Free PMC article. Clinical Trial.
Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK.
Lau DK, Luk IY, Jenkins LJ, Martin A, Williams DS, Schoffer KL, Chionh F, Buchert M, Sjoquist K, Boussioutas A, Hayes SA, Ernst M, Weickhardt AJ, Pavlakis N, Tebbutt NC, Mariadason JM. Lau DK, et al. Among authors: weickhardt aj. Mol Cancer Ther. 2021 Apr;20(4):704-715. doi: 10.1158/1535-7163.MCT-20-0836. Epub 2021 Feb 9. Mol Cancer Ther. 2021. PMID: 33563752 Clinical Trial.
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.
Chionh F, Gebski V, Al-Obaidi SJ, Mooi JK, Bruhn MA, Lee CK, Chüeh AC, Williams DS, Weickhardt AJ, Wilson K, Scott AM, Simes J, Hardingham JE, Price TJ, Mariadason JM, Tebbutt NC. Chionh F, et al. Among authors: weickhardt aj. Sci Rep. 2022 Jan 24;12(1):1238. doi: 10.1038/s41598-021-03952-y. Sci Rep. 2022. PMID: 35075138 Free PMC article. Clinical Trial.
86 results